PDF(Pubmed)
Abstract：
UNASSIGNED: Anti-neural autoantibodies associated with psychiatric syndromes is an increasing phenomenon in psychiatry. Our investigation aimed to assess the frequency and type of neural autoantibodies associated with distinct psychiatric syndromes in a mixed cohort of psychiatric patients.
UNASSIGNED: We recruited 167 patients retrospectively from the Department of Psychiatry and Psychotherapy, University Medical Center Göttingen for this study. Clinical features including the assessment of psychopathology via the Manual for Assessment and Documentation of Psychopathology in Psychiatry (AMDP), neurological examination, cerebrospinal fluid (CSF), magnetic resonance imaging (MRI) and electroencephalography (EEG) analysis were done in patients. Serum and or CSF anti- neural autoantibodies were measured in all patients for differential diagnostic reasons.
UNASSIGNED: We divided patients in three different groups: (1) psychiatric patients with CSF and/or serum autoantibodies [PSYCH-AB+, n = 25 (14.9%)], (2) psychiatric patients with CSF autoantibodies [PSYCH-AB CSF+, n = 13 (7.8%)] and (3) those psychiatric patients without autoantibodies in serum and/or CSF [PSYCH-AB-, n = 131]. The prevalence of serum neural autoantibodies was 14.9% (PSYCH-AB+), whereas 7.2% had CSF autoantibodies (PSYCH-AB CSF+) in our psychiatric cohort. The most prevalent psychiatric diagnoses were neurocognitive disorders (61-67%) and mood disorders (25-36%) in the patients presenting neural autoantibodies (PSYCH-AB+ and PSYCH-AB CSF+). However, psychiatric diagnoses, neurological deficits, and laboratory results from CSF, EEG or MRI did not differ between the three groups. To evaluate the relevance of neural autoantibody findings, we applied recent criteria for possible, probable, or definitive autoimmune based psychiatric syndromes in an paradigmatic patient with delirium and in the PSYCH-AB+ cohort. Applying criteria for any autoimmune-based psychiatric syndromes, we detected a probable autoimmune-based psychiatric syndrome in 13 of 167 patients (7.8%) and a definitive autoimmune-based psychiatric syndrome in 11 of 167 patients (6.6%).
UNASSIGNED: Neural autoantibodies were detected mainly in patients presenting neurocognitive and mood disorders in our psychiatric cohort. The phenotypical appearance of psychiatric syndromes in conjunction with neural autoantibodies did not differ from those without neural autoantibodies. More research is therefore warranted to optimize biomarker research to help clinicians differentiate patients with potential neural autoantibodies when a rapid clinical response is required as in delirium states.
UNASSIGNED: We recruited 167 patients retrospectively from the Department of Psychiatry and Psychotherapy, University Medical Center Göttingen for this study. Clinical features including the assessment of psychopathology via the Manual for Assessment and Documentation of Psychopathology in Psychiatry (AMDP), neurological examination, cerebrospinal fluid (CSF), magnetic resonance imaging (MRI) and electroencephalography (EEG) analysis were done in patients. Serum and or CSF anti- neural autoantibodies were measured in all patients for differential diagnostic reasons.
UNASSIGNED: We divided patients in three different groups: (1) psychiatric patients with CSF and/or serum autoantibodies [PSYCH-AB+, n = 25 (14.9%)], (2) psychiatric patients with CSF autoantibodies [PSYCH-AB CSF+, n = 13 (7.8%)] and (3) those psychiatric patients without autoantibodies in serum and/or CSF [PSYCH-AB-, n = 131]. The prevalence of serum neural autoantibodies was 14.9% (PSYCH-AB+), whereas 7.2% had CSF autoantibodies (PSYCH-AB CSF+) in our psychiatric cohort. The most prevalent psychiatric diagnoses were neurocognitive disorders (61-67%) and mood disorders (25-36%) in the patients presenting neural autoantibodies (PSYCH-AB+ and PSYCH-AB CSF+). However, psychiatric diagnoses, neurological deficits, and laboratory results from CSF, EEG or MRI did not differ between the three groups. To evaluate the relevance of neural autoantibody findings, we applied recent criteria for possible, probable, or definitive autoimmune based psychiatric syndromes in an paradigmatic patient with delirium and in the PSYCH-AB+ cohort. Applying criteria for any autoimmune-based psychiatric syndromes, we detected a probable autoimmune-based psychiatric syndrome in 13 of 167 patients (7.8%) and a definitive autoimmune-based psychiatric syndrome in 11 of 167 patients (6.6%).
UNASSIGNED: Neural autoantibodies were detected mainly in patients presenting neurocognitive and mood disorders in our psychiatric cohort. The phenotypical appearance of psychiatric syndromes in conjunction with neural autoantibodies did not differ from those without neural autoantibodies. More research is therefore warranted to optimize biomarker research to help clinicians differentiate patients with potential neural autoantibodies when a rapid clinical response is required as in delirium states.
摘要：
未经证实：与精神病综合征相关的抗神经自身抗体在精神病学中是一种日益增多的现象。我们的研究旨在评估混合精神病患者队列中与不同精神病综合征相关的神经自身抗体的频率和类型。
UNASSIGNED：我们从精神病学和心理治疗部门回顾性地招募了167名患者，哥廷根大学医学中心进行这项研究。临床特征，包括通过《精神病学精神病理学评估和文献手册》（AMDP）对精神病理学进行评估，神经系统检查,脑脊液（CSF），对患者进行磁共振成像（MRI）和脑电图（EEG）分析。出于鉴别诊断原因,在所有患者中测量血清和/或CSF抗神经自身抗体。
未经授权：我们将患者分为三组：（1）患有CSF和/或血清自身抗体的精神病患者[PSYCH-AB，n=25(14.9%)]，（2）精神病患者CSF自身抗体[PSYCH-ABCSF+，n=13（7.8％）]和（3）那些血清和/或CSF中没有自身抗体的精神病患者[PSYCH-AB-，n=131]。血清神经自身抗体的患病率为14.9%(PSYCH-AB+),而在我们的精神病队列中,7.2%的患者有CSF自身抗体(PSYCH-ABCSF+).在呈现神经自身抗体（PSYCH-AB和PSYCH-ABCSF）的患者中，最普遍的精神病诊断是神经认知障碍（61-67％）和情绪障碍（25-36％）。然而,精神病诊断,神经功能缺损,和脑脊液的实验室结果，三组之间的EEG或MRI没有差异。为了评估神经自身抗体结果的相关性，我们应用了最近的标准，可能,在典型的谵妄患者和PSYCH-AB+队列中，或确定的基于自身免疫的精神病综合征。适用于任何基于自身免疫的精神病综合征的标准，我们在167例患者中的13例(7.8%)发现了可能的基于自身免疫的精神病综合征,在167例患者中的11例(6.6%)发现了明确的基于自身免疫的精神病综合征.
UNASSIGNED：在我们的精神病队列中，主要在出现神经认知和情绪障碍的患者中检测到神经自身抗体。精神病综合征与神经自身抗体的表型表现与没有神经自身抗体的表型表现没有差异。因此，有必要进行更多的研究来优化生物标志物研究，以帮助临床医生在谵妄状态下需要快速临床反应时区分具有潜在神经自身抗体的患者。
UNASSIGNED：我们从精神病学和心理治疗部门回顾性地招募了167名患者，哥廷根大学医学中心进行这项研究。临床特征，包括通过《精神病学精神病理学评估和文献手册》（AMDP）对精神病理学进行评估，神经系统检查,脑脊液（CSF），对患者进行磁共振成像（MRI）和脑电图（EEG）分析。出于鉴别诊断原因,在所有患者中测量血清和/或CSF抗神经自身抗体。
未经授权：我们将患者分为三组：（1）患有CSF和/或血清自身抗体的精神病患者[PSYCH-AB，n=25(14.9%)]，（2）精神病患者CSF自身抗体[PSYCH-ABCSF+，n=13（7.8％）]和（3）那些血清和/或CSF中没有自身抗体的精神病患者[PSYCH-AB-，n=131]。血清神经自身抗体的患病率为14.9%(PSYCH-AB+),而在我们的精神病队列中,7.2%的患者有CSF自身抗体(PSYCH-ABCSF+).在呈现神经自身抗体（PSYCH-AB和PSYCH-ABCSF）的患者中，最普遍的精神病诊断是神经认知障碍（61-67％）和情绪障碍（25-36％）。然而,精神病诊断,神经功能缺损,和脑脊液的实验室结果，三组之间的EEG或MRI没有差异。为了评估神经自身抗体结果的相关性，我们应用了最近的标准，可能,在典型的谵妄患者和PSYCH-AB+队列中，或确定的基于自身免疫的精神病综合征。适用于任何基于自身免疫的精神病综合征的标准，我们在167例患者中的13例(7.8%)发现了可能的基于自身免疫的精神病综合征,在167例患者中的11例(6.6%)发现了明确的基于自身免疫的精神病综合征.
UNASSIGNED：在我们的精神病队列中，主要在出现神经认知和情绪障碍的患者中检测到神经自身抗体。精神病综合征与神经自身抗体的表型表现与没有神经自身抗体的表型表现没有差异。因此，有必要进行更多的研究来优化生物标志物研究，以帮助临床医生在谵妄状态下需要快速临床反应时区分具有潜在神经自身抗体的患者。
